Search
Now showing items 1-10 of 11
Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity
(2007)
Background: Two parallel studies evaluated safety and immunogenicity of a prophylactic HIV-1 vaccine in 192 HIV-seronegative, low-risk
volunteers. Modified vaccinia virus Ankara (MVA) and plasmid DNA (pTHr) expressed HIV-1 ...
Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials
(2008-04)
Background: An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct
of clinical trials, particularly for trials of preventive technologies such as vaccines that ...
Detection of Immune Responses in Mucosal T-cells in Kenya
(Kenya AIDs Vaccine Initiative (KAVI) University of Nairobi, 2013)
Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya Aids vaccine initiative (KAVI), Kenya
(2011)
With the persistent challenges towards controlling the HIV epidemic, there is an ongoing need for research into HIV vaccines and drugs. Sub-Saharan African countries--worst affected by the HIV pandemic--have participated ...
Anal Sex, Vaginal Practices, and HIV Incidence in Female Sex Workers in Urban Kenya: Implications for the Development of Intravaginal HIV Prevention Methods
(2011)
Multiple intravaginal HIV prevention methods, including microbicide gels, barriers, and intravaginal rings, are
in clinical development in Africa. Development of intravaginal HIV prevention products requires an understanding
of ...
CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern Africa
(2/6/2009)
Background: Clinical laboratory reference intervals have not been established in many African countries, and non-local
intervals are commonly used in clinical trials to screen and monitor adverse events (AEs) among African ...
CLSI-derived hematology and biochemistry reference intervals for healthy adults in Eastern and Southern Africa
(2009)
Clinical laboratory reference intervals have not been established in many African countries, and non-local intervals are commonly used in clinical trials to screen and monitor adverse events (AEs) among African participants. ...
CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern Africa
(2009)
Clinical laboratory reference intervals have not been established in many African countries, and non-local
intervals are commonly used in clinical trials to screen and monitor adverse events (AEs) among African participants. ...
Acceptability and Feasibility of Repeated Mucosal Specimen Collection in Clinical Trial Participants in Kenya
(2014)
Mucosal specimens are essential to evaluate compartmentalized immune responses to HIV vaccine candidates and other mucosally targeted investigational products. We studied the acceptability and feasibility of repeated mucosal ...
Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials
(2008)
An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct
of clinical trials, particularly for trials of preventive technologies such as vaccines that enroll healthy ...